Effectiveness of whey peptide and ripening extract of hop for Japanese patients of mild Alzheimer's disease

Effectiveness of whey peptide and ripening extract of hop for Japanese patients of mild Alzheimer's disease-prospective double-blind study (Kirin Alzheimer's Disease Project; KIRINAD) - KIRINAD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180222

Enrollment

Registered

2019-03-08

Start date

2018-06-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheirmer's disease Alzheirmer's disease

Interventions

1g of Whey peptide, 70 mg of matured hop bitter acids or placebo per day for every 3 months. Participant intake all 3 kinds of tablets containing test sample in crossover. 1) 0, 3, 6, 9 months post ad

ADAS-Jcog, MMSE, POMS2 Blood collections (Inflammatory marker including IL-6, ApoE, TNF-alpha, sTNF-R1, sTNF-R2, IL-1beta, IL-12, BDNF, IGF-I) 2) 3 months post administration. SPECT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Meeting the clinical criteria for Alzheimer's disease according to NINCDS-ADRDA, and features of brain MRI examination and brain blood flow of Single photon emission computed tomography (SPECT), and 17~23 of MMSE score

Exclusion criteria

Exclusion criteria: Meeting the following criteria 1) Sever cognitive impairment and no comprehensive 2) Allergy for the milk protein 3) Chronic inflammatory disease including kidney failure and collagenosis 4) Obesity in medium degree (BMI over 30) 5) Smoker or heavy alcohol drinker

Design outcomes

Primary

Measure	Time frame
ADAS-Jcog, MMSE	—

Secondary

Measure	Time frame
SPECT, Inflammatory marker, POMS2	—

Contacts

Public ContactNarimasa Katsuta

Juntendo University

nkatsuta@juntendo.ac.jp+81-3-5802-1071

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026